Journals / Kartal Eğitim ve Araştırma Hastanesi Tıp Dergisi / 2003 / Cilt: 14 - Sayı: 3

Neoadjuvant chemotherapy locally advanced carcinoma of the cervix uteri

İleri evre serviks karsinomunda neoadjuvant kemoterapi

Pages
149–152
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

NAC has obtained higher rate disease free survival.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The purpose of this study was to determine the effect of neoadjuvant chemotherapy (NAC) and to compare the efficacy of NAC with that of radiotherapy (R/T) for locally advanced cervical cancer.
📊
Key Findings & Data:The trial was performed on 31 patients (18 stage II and 13 stage III) who had completed 2 years of follow-up after treatment with neoadjuvant chemotherapy ("Quick" VBP scheme; Cisplatinum 50 mg/m2 day 1, Vincristine 1 mg/m2 day 1, Bleomycin 25 mg/m2 days 1,2,3.) with 80 patients (46 stage II and 34 stage III) who had given R/T.
💡
Conclusion & Impact:NAC has obtained higher rate disease free survival.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The purpose of this study was to determine the effect of neoadjuvant chemotherapy (NAC) and to compare the efficacy of NAC with that of radiotherapy (R/T) for locally advanced cervical cancer. The trial was performed on 31 patients (18 stage II and 13 stage III) who had completed 2 years of follow-up after treatment with neoadjuvant chemotherapy ("Quick" VBP scheme; Cisplatinum 50 mg/m2 day 1, Vincristine 1 mg/m2 day 1, Bleomycin 25 mg/m2 days 1,2,3.) with 80 patients (46 stage II and 34 stage III) who had given R/T. Four groups of patients operability status, according to tumor response were identified. Complete and partial responders were operated (radical abdominal hysterectomy and pelvic paraaortic lymphadenectomy plus R/T); stable or progressive responders were treated by R/T. The response to NAC is strongly associated with the initial median tumor diameter (MTD). The critical pretreatment diameter was 4 cm. Because of regression of clinical staging, 45.2% of the patients (14/31) in the NAC were operated. The tumor response to NAC correlated with the diameter of the cervical mass and lymph node involvement. NAC group had higher incidences, disease-free survival more than R/T group. We drawn the following conclusions: Squamous carcinoma of cervix uteri is a neoadjuvant chemosensitive tumor. Three courses of Quick VBP scheme was tolerated well by patients. NAC has obtained higher rate disease free survival.

Özet

Bu çalışmada ileri evre yassı epitel hücreli serviks karsinomunda neoadjuvant kemoterapi (NAK)'nin etkinliğini araştırmak ve aynı evredeki olgularda radyoterapi (RT) tedavi sonuçlan ile karşılaştırmak amaçlandı. Çalışma; Neoadjuvan Kemoterapi (NAK) ("Quick" VBP şeması; Sisplatin 50 mg/m2 ilk gün, Vinkristin l mg/m2 ilk gün, Bleomisin 25 mg/m2 l-3gün) sonrasında 2 yıllık izleme süresini tamamlamış 31 hasta (18'i Evre II, 13'ü Evre III) ile yalnızca RT ile tedavi görmüş 80 hasta (46'sı Evre II, 34'ü Evre III) üzerinde yapıldı. Hastalar kemoterapiye verdikleri cevaba göre 4 gruba ayrıldı. Tam ve kısmi tümör cevabı olanlar radikal histerektomi+pelvik lenfadenektomi ve postoperatif pelvik radyoterapi ile, stabil veya progresif hastalığı olanlar ise RT ile tedavi edildiler. NAK'ye cevabın başlangıçtaki tümör çapı ile ilişkili olduğu, ortalama tümör çapı 4 cm. ve altında olanların, kemoterapiye cevabının daha iyi olduğu saptandı. Hastaların %45.2'sine (14/31), NAK sonrasında klinik evreleme cerrahi yapılabilir şekilde gerilediğinden, radikal histerektomi ve pelvik lenf nodu diseksiyonu yapıldı. Kemoterapiye tümör cevabı ile servikal lezyon çapı ve lenf nodu tutulumu arasında korelasyon olduğu görüldü. NAK alan grubun kontrol grubuna göre daha yüksek oranda hastalıksız sağkalım süresine sahip oldukları gözlendi. Yassı epitel hücreli serviks kanserinin NAK'ye duyarlı olduğu, "Quick" VBP şemasını hastaların kolayca tolere ettiği, NAK'nin daha yüksek oranda hastalıksız sağkalım oram sağladığı sonucuna varıldı.

🔖

Cite This Article

ATASEVER, M., ADANALI, S., AKÖZ, İ. (2022). Neoadjuvant chemotherapy locally advanced carcinoma of the cervix uteri. Kartal Eğitim ve Araştırma Hastanesi Tıp Dergisi, Cilt: 14 - Sayı: 3, 149–152. https://ajindex.com/articles/571564

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Kenneth DH. Cervical carcinoma. In: Berek JS, Adashi EY, Hillard PA (eds). Novak’s Gynecology. Baltimore, Williams&Wilkins,1996: 1121-40
  2. Bonomi P, Blessing JA, Stehman FB. A randomized trial of three Cisplatinum dose schedules in squamous cell carcinoma of the uterine cervix. J Clin Oncol 1985; 3: 1079-85
  3. Twiggs LB, Potish RA, Mc Intrye S, Adcoc LL, Savage JE, Prem KA. Concurrent weekly cisplatinum and radiotherapy in advanced cervical cancer: A preliminary dose escalating toxicity study. Gynecol Oncol 1986; 24: 143-8
  4. Schuller DE, Wilson HE, Smith RE, Batley F, James AD. Preoperatif reductive chemotherapy for locally advanced carcinoma of the oral cavity. Cancer 1983; 81: 15-9
  5. Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma. Cancer 1987; 49: 1221-30
  6. Friedlander ML, Atkinson K, Coppleson JVM, et al. The integration of chemotherapy into the management of locally advanced cervical cancer: A pilot study. Gynecol Oncol 1984; 19: 1-7
  7. Kim DS, Moon H, Kim KT, Hwang Y, Cho S, Kim SR. Twoyear survival: Preoperatif adjuvant chemotherapy in the treatment of cervical cancer stages IB and II with bulky tumor. Gynecol Oncol 1989; 33: 225-30
  8. Benedetti PP, Greggi S, Scambia G, et al. High-dose cisplatin and bleomycin neoadjuvant chemotherapy plus radical surgery in locally advanced cervical carcinoma: Preliminary report. Gynecol Oncol 1991; 41: 212-6
  9. Sardi J, Sananes C, Giarilo A, et al. Results of the prospective randomised trial with neoadjuvant chemotherapy in stage IB, bulky, squamous carcinoma of cervix. Gynecol Oncol 1993; 49: 156-65
  10. Scarabelli C, Zarreli A, Gallo A, Visentin MC. Multimodal treatment with neoadjuvant intraarterial chemotherapy and radical surgery in patients with stage IIIB-IVA cervical cancer. Cancer 1995; 76: 1019-26
  11. Souhami L, Gil RA, Allan SE, et al. A randomized trial of chemotherapy followed by pelvic radiation therapy in stage IIIB carcinoma of the cervix. J Clin Oncol 1991; 9: 970-7
  12. Tattersal MHN, Lorvidhaya V, Vootiprux V, et al. Randomized trial of epirubucin and cisplatin chemotherapy followed by pelvic radiation in locally advanced cervical cancer. J Clin Oncol 1995; 13: 444 -51
  13. Sardi J, Sananes C, Giaroli A, Maya G, Di Paola G. Neoadjuvant chemotherapy in locally advanced carcinoma of the cervix uteri. Gynecol Oncol 1990; 38: 486-93
  14. Sardi J, Di Paola G, Cachau A, et al. A possible new trend in the management of carcinoma cervix uteri. Gynec